liu.seSearch for publications in DiVA
Endre søk
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
Effects of adjuvant tamoxifen over three decades on breast cancerefree and distant recurrence-free interval among premenopausal women with oestrogen receptor-positive breast cancer randomised in the Swedish SBII:2pre trial
Linköpings universitet, Institutionen för klinisk och experimentell medicin. Linköpings universitet, Medicinska fakulteten. Dept Oncol, Jönköping, Sweden; Lund Univ, Sweden.
Lund Univ, Sweden.
Lund Univ, Sweden.
Linköpings universitet, Institutionen för klinisk och experimentell medicin, Avdelningen för Kirurgi, Ortopedi och Onkologi. Linköpings universitet, Medicinska fakulteten. Region Östergötland, Centrum för kirurgi, ortopedi och cancervård, Onkologiska kliniken US.
Vise andre og tillknytning
2019 (engelsk)Inngår i: European Journal of Cancer, ISSN 0959-8049, E-ISSN 1879-0852, Vol. 110, s. 53-61Artikkel i tidsskrift (Fagfellevurdert) Published
Abstract [en]

Aims: The primary aim was to compare 2 years of adjuvant tamoxifen versus no systemic treatment in premenopausal patients with oestrogen receptor (ER) epositive tumours, regarding breast cancerefree interval (BCFi) and distant recurrenceefree interval (D-RFi), with 30 years of follow-up and for specified intervals. Moreover, we aimed to investigate the effects of adjuvant tamoxifen on the incidence of secondary malignancies and survival after distant recurrence. Methods: Premenopausal patients with primary breast cancer were randomised to 2 years of tamoxifen (n=277) or no systemic treatment (n=287), irrespective of ER status. Information regarding events was collected by a review of medical records and from national registers. Results: The median follow-up for all patients without events was 28 years, and only four of the patients alive had a follow-up of amp;lt;20 years. With 30 years of follow-up, tamoxifen prolonged BCFi in the intention-to-treat population (hazard ratio [HR] = 0.76, 95% confidence interval (CI) 0.61-0.94, p = 0.011) compared with no treatment. In patients with ER-positive tumours (n = 362), tamoxifen prolonged BCFi (HR = 0.62, 95% CI 0.47-0.82, p = 0.001) and D-RFi (HR = 0.73, 95% CI 0.54-0.99, p = 0.043). The positive effect on BCFi was significant also for the interval amp;gt; 15-30 years (HR = 0.53, 95% CI 0.28-0.98, p = 0.042). For patients with ER-positive tumours who were diagnosed with distant recurrence (n=165), survival after distant recurrence was shorter among tamoxifen-treated patients (median, 29 months versus 43 months). The incidence of contralateral breast cancer was 42% lower in the tamoxifen group (HR=0.58, 95% CI 0.35-0.96, p=0.035), whereas no differences were observed regarding other secondary malignancies. Conclusions: With three decades of follow-up, 2 years of adjuvant tamoxifen reduced the incidence of breast cancererelated events and distant recurrence, and the carryover effect seems to extend beyond 15 years. Moreover, adjuvant tamoxifen seems to be associated with shorter survival after diagnosis of distant recurrence. (C) 2019 The Authors. Published by Elsevier Ltd.

sted, utgiver, år, opplag, sider
ELSEVIER SCI LTD , 2019. Vol. 110, s. 53-61
Emneord [en]
Adjuvant therapy; Tamoxifen; Premenopausal; Long-term follow-up
HSV kategori
Identifikatorer
URN: urn:nbn:se:liu:diva-155552DOI: 10.1016/j.ejca.2018.12.034ISI: 000460123000009PubMedID: 30769227OAI: oai:DiVA.org:liu-155552DiVA, id: diva2:1299388
Merknad

Funding Agencies|Futurum-the Academy of Health and Care; Jonkoping County Council; Foundation for Clinical Cancer Research in Jonkoping; FORSS (Medical Research Council of Southeast Sweden); Gunnar Nilsson Cancer Foundation; Mrs. Berta Kamprad Foundation; Anna and Edwin Bergers Foundation; Swedish Cancer and Allergy Foundation; Governmental Funding of Clinical Research within the Swedish National Health Service; Swedish Cancer Society

Tilgjengelig fra: 2019-03-26 Laget: 2019-03-26 Sist oppdatert: 2019-06-04

Open Access i DiVA

fulltext(765 kB)48 nedlastinger
Filinformasjon
Fil FULLTEXT01.pdfFilstørrelse 765 kBChecksum SHA-512
6a2b87422800fa69216f9f77a94a927f02dbd604f01513333d31f46b668eaa41c4d8f14b06e876dda05028c004e32dfe031d2a39a70117b6a35dc3ee701d132c
Type fulltextMimetype application/pdf

Andre lenker

Forlagets fulltekstPubMed

Søk i DiVA

Av forfatter/redaktør
Ekholm, MariaNordenskjöld, BoStål, Olle
Av organisasjonen
I samme tidsskrift
European Journal of Cancer

Søk utenfor DiVA

GoogleGoogle Scholar
Totalt: 48 nedlastinger
Antall nedlastinger er summen av alle nedlastinger av alle fulltekster. Det kan for eksempel være tidligere versjoner som er ikke lenger tilgjengelige

doi
pubmed
urn-nbn

Altmetric

doi
pubmed
urn-nbn
Totalt: 102 treff
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf